

13th August, 2026

To,
The Manager - Corporate Relationship
Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: NSE - KILITCH

Sub: Outcome of the Board Meeting

Dear Sir,

Pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, 13th August, 2026 have considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith.

The Board Meeting commenced at 16:30 hours and concluded at 20.40 hours.

Request you to kindly take note of the same and acknowledge the receipt.


Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director
DIN: 00147876




KILITCH DRUGS (INDIA) LIMITED STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com CIN:L24239MH1992PLC066718 (Rs. In Lakhs except Earnings per Share data)				
		Three Months Ended		Year Ended
		30-06-2026	31-03-2026	30-06-2025
		Unaudited	Audited	Unaudited
				31-03-2026
				Audited
1	Income			
	Net Sales/ Income from operations	4,091.20	7,196.88	3,412.20
	Other Income	354.76	113.63	349.52
	Total Income	4,445.96	7,310.51	3,761.72
2	Expenses			
	Cost of Materials Consumed	2,024.54	2,853.23	1,826.71
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(19.81)	146.91	(76.09)
	Employee Benefit Expenses	352.50	361.37	239.50
	Finance Cost	48.63	57.79	58.66
	Depreciation and Amortisation Expenses	75.86	70.14	49.87
	Export Product Registration/Commission	519.77	522.98	550.50
	Other Expenses	749.66	1,365.41	514.40
	Total Expenses	3,751.16	5,377.83	3,163.55
3	Profit / (Loss) before Exceptional items (1-2)	694.80	1,932.68	598.17
4	Exceptional Items	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	694.80	1,932.68	598.17
6	Less: Tax Expenses:-			
	Current Tax	161.17	617.90	129.86
	Deferred Tax	28.38	(85.12)	(11.10)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	505.24	1,399.90	479.41
8	Other Comprehensive Income (after tax)	500.21	(321.17)	293.49
9	Total Comprehensive Income (after taxes) (7+8)	1,005.46	1,078.73	772.90
10	Paid-Up equity share capital (Face Value Rs 10 per share)	3,496.16	3,496.16	1,608.23
11	Other Equity			29,804.51
12	Earning per share (not annualised)			
	(a) Basic	1.45	4.08	1.49
	(b) Diluted	1.45	4.08	1.49
Notes: 1. The above Unaudited Standalone Financial Results of the Company for the quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August, 2026. 2. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108. 3. The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors. 4. The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods.				
Place : Mumbai Dated: 13th Aug, 2026		For and on behalf of the Board of Directors  Mira Menta Managing Director DIN:- 01902831		

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter ended 30th June, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, C. Sharat & Associates
Chartered Accountants
FRN: 128593W


Chintan Sharatchandra Shah
Partner
Mem.No: 127551
UDIN No: 26127551CQMGKK7150
Place: Mumbai
Date:13/08/2026



KILITCH DRUGS (INDIA) LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED			
		Three Months Ended		Year Ended	
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited	Unaudited	Audited
1	Income				
	Net Sales/Income from Operations	4,487.89	8,960.27	4,313.98	23,547.49
	Other Income	289.69	49.27	255.74	1,123.86
	Total Income	4,777.58	9,009.54	4,569.72	24,671.35
2	Expenses				
	Cost of Materials Consumed	2,391.57	4,268.56	2,622.27	12,506.59
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(19.81)	146.91	(76.09)	106.73
	Employee Benefit Expenses	413.63	428.71	275.19	1,430.58
	Finance Cost	87.64	144.44	152.98	556.08
	Depreciation and Amortisation Expenses	109.33	98.05	84.32	362.31
	Export Product Registration/Commission	519.77	523.59	550.87	2,140.24
	Other expenses	889.16	1,378.23	615.28	3,703.38
	Total Expenses	4,391.29	6,988.49	4,224.82	20,805.91
3	Profit before Exceptional items (1-2)	386.29	2,021.05	344.90	3,865.44
4	Exceptional Items	-	-	-	-
5	Profit from ordinary activities before tax (3+4)	386.29	2,021.05	344.90	3,865.44
6	Less : Tax Expenses				
	Current Income Tax	161.17	617.90	129.86	1,085.69
	Deferred Tax	28.38	(85.13)	(11.21)	(170.28)
7	Profit after tax for the period from continuing operations (5-6)	196.74	1,488.28	226.25	2,950.03
8	Net Profit/(Loss) After Tax & Share in Profits /(Loss) of Associates	196.74	1,488.28	226.25	2,950.03
9	Other Comprehensive Income (after Tax)	500.21	(321.17)	293.49	(106.50)
10	Total Comprehensive Income (after taxes) (8+9)	696.95	1,167.11	519.74	2,843.53
11	Net Profit / (Loss) attributable to				
	a) Owner of the Company	291.30	1,451.85	302.59	3,016.64
	b) Non Controlling interest	(94.56)	36.43	(76.34)	(66.61)
12	Other Comprehensive Income attributable to				
	a) Owner of the Company	500.21	(321.17)	293.49	(106.50)
	b) Non Controlling interest	-	-	-	-
13	Total Income attributable to				
	a) Owner of the Company	791.51	1,130.68	596.08	2,910.14
	b) Non Controlling interest	(94.56)	36.43	(76.34)	(66.61)
14	Paid-Up equity share capital (Face Value Rs. 10 per share)	3,496.16	3,496.16	1,608.23	3,496.16
15	Other Equity				24,469.17
16	Earning per share (not annualised)				
	(a) Basic	0.83	4.24	0.94	8.91
	(b) Diluted	0.83	4.24	0.94	8.91


Notes:

- The above Unaudited Consolidated Financial Results of the Company for the quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13th August, 2026.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
- The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.



For and on behalf of the Board of Directors

Mira Mehta
Managing Director
DIN:- 01902831



Place: Mumbai
Date: 13th August, 2026

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
**The Board of Directors of
Kilitch Drugs (India) Limited**


1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th June, 2026 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
 2. Kilitch Estro Biotech PLC – Foreign Subsidiary
5. (a) We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total revenues of Rs. Nil, total Net Profit/(Loss) after tax of Rs. (22.00) Lakhs and total comprehensive income/(loss) of Rs. (22.00) Lakhs for the quarter ended 30th June, 2026. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the



Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.

(b)The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total revenues of Rs. 396.69 Lakhs, total net profit/(loss) after tax of Rs. (286.54) Lakhs and total comprehensive income/(loss) of Rs. (286.54) Lakhs for the quarter ended 30th June, 2026. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management.

Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, C. Sharat & Associates

Chartered Accountants

FRN: 128593W

Chintan Sharatchandra Shah

Partner

Mem.No: 127551

UDIN No: 26127551OZZJD7689

Place: Mumbai

Date:13/08/2026

